THE BUSINESS OF BIOTECH

37:00 24_01_BoB_1280x720_Ep241
BoB@JPM: Ran Zheng, Landmark Bio

Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a disc...

ABOUT THE BUSINESS OF BIOTECH

Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success.

FEATURED GUESTS

Ran Zheng
Landmark Bio
PLAY
Peter Anastasiou
Capsida Biotherapeutics
PLAY
Stefan Scherer
3T Bioscience
PLAY
Jim Doherty
Acumen Pharmaceuticals
PLAY
Andrey Doronichev
BIOPTIC
PLAY
Jeff Coller
Johns Hopkins University RNA Innovation Center
PLAY
Michelle Kim
Johns Hopkins University RNA Innovation Center
PLAY
Tal Zaks
Exsilio Therapeutics
PLAY
Alexandria Forbes
MeiraGTx
PLAY
Vikram Bajaj
Foresite Capital
PLAY

MEET THE HOST

Matty PHosted by Bioprocess Online Chief Editor Matt Pillar, The Business of Biotech brings you weekly intelligence and insight, from leading voices in the biotech industry.

Interested in joining us on air? Contact us